GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.

MLA

Ferracini, Amanda Canato, et al. “GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.” Clinical and Translational Science, vol. 14, no. 2, Mar. 2021, pp. 720–28. EBSCOhost, https://doi.org/10.1111/cts.12937.

APA

Ferracini, A. C., Lopes-Aguiar, L., Lourenço, G. J., Yoshida, A., Lima, C. S. P., Sarian, L. O., Derchain, S., Kroetz, D. L., & Mazzola, P. G. (2021). GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer. Clinical and Translational Science, 14(2), 720–728. https://doi.org/10.1111/cts.12937

Chicago

Ferracini, Amanda Canato, Leisa Lopes-Aguiar, Gustavo Jacob Lourenço, Adriana Yoshida, Carmen Silva Passos Lima, Luis Otávio Sarian, Sophie Derchain, Deanna L Kroetz, and Priscila Gava Mazzola. 2021. “GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.” Clinical and Translational Science 14 (2): 720–28. doi:10.1111/cts.12937.